Stockscreener 앱 받기
126.47
0.16%
-0.17
전일 마감가:
$126.64
열려 있는:
$126.96
하루 거래량:
1.73M
Relative Volume:
0.25
시가총액:
$156.95B
수익:
$29.05B
순이익/손실:
$8.11B
주가수익비율:
19.59
EPS:
6.4563
순현금흐름:
$9.16B
1주 성능:
+1.89%
1개월 성능:
+4.55%
6개월 성능:
+17.76%
1년 성능:
+40.19%
1일 변동 폭
$126.29
$128.25
1주일 범위
$123.32
$128.70
52주 변동 폭
$88.57
$128.70
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
126.50 | 157.12B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,065.96 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.28 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.54 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
127.12 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.66 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead - TradingView
Prudential Financial Inc. Buys 486,379 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation (NASDAQ: GILD) pledges $3M+ grants to 14 groups tackling hunger - Stock Titan
Gilead Sciences, Inc. $GILD Shares Bought by Nemes Rush Group LLC - MarketBeat
Truist Securities assumes coverage on Gilead Sciences stock with Buy rating - Investing.com
Gilead Sciences, Inc. $GILD Shares Bought by MAI Capital Management - MarketBeat
Centric Wealth Management Purchases 2,736 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Charles Schwab Investment Management Inc. Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Sprint Bioscience Surges After Selling Cancer Program to Gilead Sciences - MarketScreener
Sprint Bioscience sells the TREX1 program to Gilead - TradingView
Is Ameya Precision Engineers Limited a Safe Haven Stock During Market StressTrade Execution Strategies & See Risk Factors Before Making Any Move - earlytimes.in
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
TD Waterhouse Canada Inc. Sells 120,736 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Rhumbline Advisers - MarketBeat
Mufg Securities Americas Inc. Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Journey Strategic Wealth LLC Buys 4,053 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
DNB Asset Management AS Purchases 61,277 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
American Century Companies Inc. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Legal & General Group Plc Sells 487,170 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Mediolanum International Funds Ltd Purchases 82,402 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Swiss National Bank Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Handelsbanken Fonder AB Buys 69,440 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Rockefeller Capital Management L.P. Decreases Position in Gilead Sciences, Inc. $GILD - MarketBeat
CFC Planning Co LLC Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Brandywine Global Investment Management LLC Sells 5,650 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
First Deliveries of Gilead's Twice-Yearly HIV Prevention Therapy in Sub-Saharah Africaand What it Means for Ending the HIV Epidemic - Gilead Sciences
Gilead (GILD) Unit Receives FDA Orphan Drug Designation - GuruFocus
Gilead Sciences (GILD) Receives Upgrade Amid HIV Division Streng - GuruFocus
Mizuho Adjusts Price Target on Gilead Sciences to $140 From $131, Maintains Outperform Rating - MarketScreener
Prudential PLC Sells 27,809 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Mizuho raises Gilead Sciences stock price target to $140 on HIV outlook - Investing.com
Ensign Peak Advisors Inc Buys 152,685 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
How Gilead’s Lenacapavir Launch and New HIV Data May Shape GILD’s Global Outlook - simplywall.st
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength (GILD) - Seeking Alpha
South Africa is urged by advocates to issue a compulsory license for Gilead's HIV prevention drug - statnews.com
Gilead’s Top Lawyer Leaving After Big Stock Sale, Settlements - Bloomberg Law News
Gilead Sciences (NASDAQ:GILD) Reaches New 1-Year HighHere's What Happened - MarketBeat
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $673,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock enhance shareholder value2025 Support & Resistance & Advanced Technical Signal Analysis - newser.com
Will Gilead Sciences Inc. (GIS) stock outperform energy sector in 2025Weekly Market Report & Verified Stock Trade Ideas - newser.com
Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets - Yahoo Finance
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock outperform Dow JonesQuarterly Trade Summary & Precise Swing Trade Alerts - newser.com
Identifying reversal signals in Gilead Sciences Inc.July 2025 Highlights & Expert Approved Momentum Ideas - newser.com
Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Can Gilead Sciences Inc. stock beat market expectations this quarter2025 Stock Rankings & Long-Term Investment Growth Plans - newser.com
Why Gilead Sciences Inc. (GIS) stock is a strong analyst pick2025 Price Action Summary & Long-Term Growth Plans - newser.com
Is Gilead Sciences Inc. (GIS) stock dividend growth reliableVolume Spike & Daily Market Momentum Tracking - newser.com
Gilead Sciences' GC Will Leave Co. Next Month - Law360
Is Gilead Sciences Inc. stock near bottom after declineWeekly Trend Summary & Fast Moving Trade Plans - newser.com
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
135,193 |
| Mercier Johanna | Chief Commercial Officer |
Nov 17 '25 |
Sale |
125.86 |
28,000 |
3,524,173 |
107,193 |
6.16%
1.27%
자본화:
|
볼륨(24시간):